Authors: Muller, DN Heissmeyer, V Dechend, R Hampich, F Park, JK Fiebeler, A Shagdarsuren, E Theuer, J Elger, M Pilz, B Breu, V Schroer, K Ganten, D Dietz, R Haller, H Scheidereit, C Luft, FC

Citation: Dn. Muller et al., Aspirin inhibits NF-kappa B and protects from angiotensin II-induced organdamage, FASEB J, 15(8), 2001, pp. NIL_117-NIL_135

Authors: Heissmeyer, V Krappmann, D Hatada, EN Scheidereit, C

Citation: V. Heissmeyer et al., Shared pathways of I kappa B kinase-induced SCF beta TrCP-mediated ubiquitination and degradation for the NF-kappa B precursor p105 and I kappa B alpha, MOL CELL B, 21(4), 2001, pp. 1024-1035

Authors: Krappmann, D Patke, A Heissmeyer, V Scheidereit, C

Citation: D. Krappmann et al., B-cell receptor- and phorbol ester-induced NF-kappa B and c-Jun N-terminalkinase activation in B cells requires novel protein kinase C's, MOL CELL B, 21(19), 2001, pp. 6640-6650

Authors: Kordes, U Krappmann, D Heissmeyer, V Ludwig, WD Scheidereit, C

Citation: U. Kordes et al., Transcription factor NF-kappa B is constitutively activated in acute lymphoblastic leukemia cells, LEUKEMIA, 14(3), 2000, pp. 399-402

Authors: Dechend, R Hirano, F Lehmann, K Heissmeyer, V Ansieau, S Wulczyn, FG Scheidereit, C Leutz, A

Citation: R. Dechend et al., The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel andnuclear co-regulators, ONCOGENE, 18(22), 1999, pp. 3316-3323

Authors: Heissmeyer, V Krappmann, D Wulczyn, FG Scheidereit, C

Citation: V. Heissmeyer et al., NF-kappa B p105 is a target of I kappa B kinases and controls signal induction of Bcl-3-p50 complexes, EMBO J, 18(17), 1999, pp. 4766-4778